Targeted treatment study for dilated cardiomyopathy
Part of Genetic & congenital, Heart & circulation clinical trials.
This study tests whether a personalized treatment approach can improve heart function in people with dilated cardiomyopathy (a condition where the heart becomes enlarged and weak). It focuses on patients who still have low heart function despite standard medications.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have been diagnosed with dilated cardiomyopathy (an enlarged, weak heart).
- Your heart function is low (ejection fraction less than 45%) and your heart is enlarged.
- You have normal or high cholesterol and triglycerides (fats in your blood).
- You have been on heart failure medications for at least 1–3 months (depending on your situation) and still have poor heart function.
- You do not have liver or kidney problems, have not had heart surgery recently, and are not taking certain other medicines.
- You are not pregnant and are willing to avoid pregnancy during the study.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests if danicamtiv can improve heart function in people with dilated cardiomyopathy caused by certain genetic changes. It may help those who have stable symptoms but still need more treatment options.
This study tests whether people with dilated cardiomyopathy whose heart function has already recovered to normal can safely stop or reduce one of their heart medications while staying in remission. It aims to find the best way to keep the heart healthy without extra medicines.
This study looks at how small blood vessels in the heart affect outcomes in people with dilated cardiomyopathy (an enlarged, weak heart). You may qualify if you have heart failure with a weak pump and no significant blockages in your main heart arteries.
This trial tests whether combining modern heart failure medications with an implantable defibrillator (ICD) can reduce the risk of dangerous heart rhythms and improve survival in people with dilated cardiomyopathy. It focuses on those with a weak heart pump and specific scarring seen on MRI.
This study looks at whether certain antibodies (proteins in your blood) can help predict how dilated cardiomyopathy will progress. By testing your blood, researchers hope to learn more about your condition and find better ways to manage it.
This trial tests whether a high-fat diet can help change how your heart uses energy, potentially improving heart function in people with non-ischemic heart failure.
Hear when a new Dilated Cardiomyopathy trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.